findmyKOL
Clinical trialNCT01706523TerminatedPhase 3Interventional

Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders

SponsorSeaside Therapeutics, Inc.Enrollment165Autism Spectrum Disorders
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

25 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Southwest Autism Research & Resource Center

    Phoenix, Arizona, United States

  • University of California-Los Angeles Neuropsychiatric Institute

    Los Angeles, California, United States

  • Ucdavis M.I.N.D Insitute

    Sacramento, California, United States

  • Pharmax Research Clinic

    Miami, Florida, United States

  • Lake Mary Pediatrics

    Orange City, Florida, United States

  • Institute for Behavioral Medicine

    Smyrna, Georgia, United States

  • Institute for Juvenile Research

    Chicago, Illinois, United States

  • Riley Hospital for Children

    Indianapolis, Indiana, United States

  • Kennedy Krieger Institute

    Baltimore, Maryland, United States

  • Boston Children'S Hospital

    Boston, Massachusetts, United States

  • University of Massachusetts

    Worcester, Massachusetts, United States

  • University of Missouri, Thompson Research Center for Autism & Neurodevelopmental Disorders

    Columbia, Missouri, United States

  • Seaver Autism Center, Mount Sinai Medical Center

    New York, New York, United States

  • Nys Institute for Basic Research in Developmental Disabilities

    Staten Island, New York, United States

  • Unc Chapel Hill Department of Psychiatry

    Chapel Hill, North Carolina, United States

  • Akron Children'S Hospital

    Akron, Ohio, United States

  • Cutting Edge Research

    Oklahoma City, Oklahoma, United States

  • Summit Research Network

    Portland, Oregon, United States

  • Suburban Research Associates

    Media, Pennsylvania, United States

  • Children'S Hospital of Philadelphia

    Philadelphia, Pennsylvania, United States

  • University of Tennessee Medical Group, Lebonheur Children'S Hospital

    Memphis, Tennessee, United States

  • Vanderbilt Kennedy Center

    Nashville, Tennessee, United States

  • Red Oaks Psychiatry Associates, P.A.

    Houston, Texas, United States

  • Road Runner Research

    San Antonio, Texas, United States

  • Seattle Children'S Hospital

    Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Nov 2011
Primary completion
31 Jul 2013
Completion
31 Jul 2013
Last update posted
31 Jul 2013
Registered enrollment
165
Registry id
NCT01706523

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.